Roche Holding (ROG) Hisse Özeti

Roche Holding AG, Avrupa, Kuzey Amerika, Latin Amerika, Asya, Afrika, Avustralya ve Yeni Zelanda'da ilaç ve diagnostik alanlarında faaliyet göstermektedir. Daha fazla detay

ROG temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	1/6
Finansal Sağlık	4/6
Temettüler	5/6

Ödüller

Adil değer tahminimizden 63.4% daha düşük bir oranda işlem görüyor

Kazançların yılda 12.51% oranında artması öngörülüyor

3.75% oranında güvenilir bir temettü öder

Risk Analizi

Finansal sonuçları etkileyen büyük tek seferlik kalemler

Yüksek borç seviyesine sahip

ROG Community Fair Values

Create Narrative

See what 223 others think this stock is worth. Follow their fair value or set your own to get alerts.

Roche Holding

AnalystConsensusTarget

Based on Analyst Price Targets

Diagnostics, Pipeline And Automation Will Fuel Future Success

Key Takeaways Expanding innovative diagnostics and advancing high-value biologics pipelines position Roche for strong global growth and resilient revenues across diverse markets. Strategic investments in automation, AI, and emerging markets drive margin expansion, lower costs, and reduce reliance on older, patent-sensitive products.

View narrative

CHF 298.64

13.3% değerinin altında

1.94%

Revenue growth p.a.

137

Roche Holding

bazza

Community Contributor

Roche Holding will see a 4.2576% revenue growth shaking the market

Valuation ### **Analyse der Roche Jahreszahlen 2024: Wachstum setzt sich fort, Herausforderungen bleiben_20250130 #### Zusammenfassung der Ergebnisse Roche hat für das Jahr 2024 ein solides Wachstum von 7 % auf 60,5 Mrd. CHF erzielt, was die Erwartungen leicht übertroffen hat.

View narrative

CHF 302.06

14.3% değerinin altında

5.07%

Revenue growth p.a.

Roche Holding

AnalystLowTarget

Community Contributor

Regulatory Scrutiny And Generic Competition Will Erode Pricing Power

Key Takeaways Intensifying global pricing reforms, increasing biosimilar competition, and mounting regulatory demands will significantly pressure Roche's revenue, margins, and long-term profitability. Rising R&D costs, disruptive new technologies, and shifting payer priorities threaten Roche's innovation pipeline and ability to sustain premium pricing for novel therapies.

View narrative

CHF 230

12.6% aşırı değerlenmiş

-0.12%

Revenue growth p.a.

View Stock Community

Roche Holding AG Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Roche Holding
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	CHF 258.90
52 Haftanın En Yüksek Seviyesi	CHF 313.80
52 Haftanın En Düşük Seviyesi	CHF 231.90
Beta	0.18
1 Aylık Değişim	-9.73%
3 Aylık Değişim	1.53%
1 Yıllık Değişim	-5.20%
3 Yıllık Değişim	-20.68%
5 Yıllık Değişim	-19.27%
Halka arzdan bu yana değişim	891.95%

Son Haberler & Güncellemeler

Recent updates

Investors Still Waiting For A Pull Back In Roche Holding AG (VTX:ROG)

Aug 20

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Jun 24

Roche Holding (VTX:ROG) Will Pay A Larger Dividend Than Last Year At CHF9.70

Mar 17

Roche Holding (VTX:ROG) Has A Pretty Healthy Balance Sheet

Mar 16

Roche Holding (VTX:ROG) Is Increasing Its Dividend To CHF9.70

Feb 23

Roche Holding (VTX:ROG) Is Paying Out A Larger Dividend Than Last Year

Feb 09

Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear

Feb 05

Roche Holding will see a 4.2576% revenue growth shaking the market

Feb 04### **Analyse der Roche Jahreszahlen 2024: Wachstum setzt sich fort, Herausforderungen bleiben_20250130 #### Zusammenfassung der ErgebnisseRoche hat für das Jahr 2024 ein solides Wachstum von 7 % auf

Advancing 7 New Therapies And Poseida Acquisition Will Expand Presence In Oncology By 2025

Feb 02 Successful Pharma pipeline and innovative diagnostics launches are anticipated to drive long-term revenue growth and operating profit.

Roche Holding AG (VTX:ROG) Could Be Riskier Than It Looks

Nov 25

Hissedar Getirileri

	ROG	CH Pharmaceuticals	CH Pazar
7D	-4.5%	-3.4%	-2.0%
1Y	-5.2%	3.9%	2.3%

Getiri vs. Endüstri: ROG geçen yıl % 3.9 oranında getiri sağlayan Swiss Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: ROG geçen yıl % 2.3 oranında getiri sağlayan Swiss Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is ROG's price volatile compared to industry and market?
ROG volatility
ROG Average Weekly Movement	3.7%
Pharmaceuticals Industry Average Movement	4.1%
Market Average Movement	3.4%
10% most volatile stocks in CH Market	7.5%
10% least volatile stocks in CH Market	1.7%

İstikrarlı Hisse Senedi Fiyatı: ROG son 3 ayda Swiss piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: ROG 'nin haftalık oynaklığı ( 4% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1896	103,249	Thomas Schinecker	www.roche.com

Roche Holding AG, Avrupa, Kuzey Amerika, Latin Amerika, Asya, Afrika, Avustralya ve Yeni Zelanda'da ilaç ve diagnostik alanlarında faaliyet göstermektedir. Şirket, anemi, kan ve solid tümörler, dermatoloji, hemofili, enflamatuar ve otoimmün, nörolojik bozukluklar, oftalmoloji, solunum bozuklukları ve transplantasyon terapötik alanlarında ilaç çözümleri sunmaktadır. Ayrıca kanser, diyabet, Covid-19, hepatit, insan papilloma virüsü ve diğerleri gibi çeşitli hastalıkların teşhisi için in vitro testler; teşhis cihazları ve dijital sağlık çözümleri sunmaktadır.

Roche Holding AG Temel Bilgiler Özeti

Roche Holding'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ROG temel i̇stati̇sti̇kler
Piyasa değeri	CHF 222.22b
Kazançlar(TTM)	CHF 9.43b
Gelir(TTM)	CHF 63.49b

23.3x

F/K Oranı

3.5x

P/S Oranı

ROG aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ROG gelir tablosu (TTM)
Gelir	CHF 63.49b
Gelir Maliyeti	CHF 16.01b
Brüt Kâr	CHF 47.48b
Diğer Giderler	CHF 38.05b
Kazançlar	CHF 9.43b

Son Raporlanan Kazançlar

Jun 30, 2025

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	11.09
Brüt Marj	74.79%
Net Kâr Marjı	14.85%
Borç/Özkaynak Oranı	100.0%

ROG uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

3.7%

Mevcut Temettü Verimi

82%

Ödeme Oranı

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/11/02 07:31
Gün Sonu Hisse Fiyatı	2025/10/31 00:00
Kazançlar	2025/06/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Roche Holding AG 49 Bu analistlerden 15, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
John Staszak	Argus Research Company
Gerhard Schwarz	Baader Helvea Equity Research
Mark Purcell	Barclays

Roche Holding (ROG) Hisse Özeti

Ödüller

Risk Analizi

Diagnostics, Pipeline And Automation Will Fuel Future Success

Roche Holding will see a 4.2576% revenue growth shaking the market

Regulatory Scrutiny And Generic Competition Will Erode Pricing Power

Roche Holding AG Rakipler

Novartis

Galderma Group

Sandoz Group

Dottikon ES Holding

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Roche Holding AG (SWX:ROG) completed the acquisition of 89bio, Inc. (NasdaqGM:ETNB) in a tender offer transaction.

Roche Announces Positive Phase III Results for Gazyva/Gazyvaro in Children and Young Adults with Idiopathic Nephrotic Syndrome

Roche Announces Appointment of Nina Schwab-Hautzinger as Head of Group Communications and Member of the Enlarged Corporate Executive Committee, Effective 1 February 2026

Cmedsir Announces the Positive Results of Its Empress Study, Conducted in Collaboration with Roche Farma

FDA Approves Genentech's Gazyva for the Treatment of Lupus Nephritis

Roche’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People with ER-Positive Advanced Breast Cancer

Recent updates

Roche Holding AG (SWX:ROG) completed the acquisition of 89bio, Inc. (NasdaqGM:ETNB) in a tender offer transaction.

Roche Announces Positive Phase III Results for Gazyva/Gazyvaro in Children and Young Adults with Idiopathic Nephrotic Syndrome

Roche Announces Appointment of Nina Schwab-Hautzinger as Head of Group Communications and Member of the Enlarged Corporate Executive Committee, Effective 1 February 2026

Cmedsir Announces the Positive Results of Its Empress Study, Conducted in Collaboration with Roche Farma

FDA Approves Genentech's Gazyva for the Treatment of Lupus Nephritis

Roche’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People with ER-Positive Advanced Breast Cancer

Roche Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema

CHMP Recommends EU Approval of Roche's Gazyva/Gazyvaro for Lupus Nephritis

Roche Receives CE Mark for AI-Based Kidney Klin Risk Algorithm and Launches New Comprehensive Chronic Kidney Disease (CKD) Algorithm Panel

Claudia Süssmuth Dyckerhoff Decides Not to Stand for Re-Election as a Member of the Roche Board of Directors

Roche Announces Primary Results from the TSIX Study Program

Roche Presents New Data for OCREVUS and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025

Roche S.A. Announces Positive Phase III Results Show Roche's Giredestrant Significantly Improved Pro progression-Free Survival in ER-Positive Advanced Breast Cancer

CHMP Recommends EU Approval of Roche's Subcutaneous Formulation of Lunsumio for People with Relapsed or Refractory Follicular Lymphoma

Roche Achieves First CLIA 'Moderate Complexity' categorization for Ionify®? 25-Hydroxy Vitamin D Total Test

Roche Announces New Data Reinforcing Efficacy and Safety of Vabysmo in Treating nAMD

Investors Still Waiting For A Pull Back In Roche Holding AG (VTX:ROG)

Roche's First Respiratory Test Powered by TAGS Technology Receives FDA Clearance for SARS-CoV-2, Influenza A, Influenza B and RSV

First half 2025 earnings released: EPS: CHF9.31 (vs CHF7.85 in 1H 2024)

Roche Announces its New Innovations In-Booth at Association for Diagnostics & Laboratory Medicine Scientific Meeting and Clinical Lab Expo

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Roche Holding AG, Annual General Meeting, Sep 10, 2025

Investor sentiment deteriorates as stock falls 15%

Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer's At Ad/Pd 2025

Roche Holding AG Provides Update on Phase III Ocrevus High Dose Study in People with Relapsing Multiple Sclerosis

Roche Holding AG Approves Dividend

Roche Announces Management Changes

Upcoming dividend of CHF9.70 per share

Roche Holding (VTX:ROG) Will Pay A Larger Dividend Than Last Year At CHF9.70

Roche Holding AG to Present New Data At the Muscular Dystrophy Association Conference from 16-19 March, 2025

Roche Holding (VTX:ROG) Has A Pretty Healthy Balance Sheet

Roche Announces CHMP Recommends EU Approval of Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Roche Holding (VTX:ROG) Is Increasing Its Dividend To CHF9.70

Roche Unveils New Class of Next-Generation Sequencing with Its Novel Sequencing by Expansion Technology

Roche Elecsys sFlt-1/PlGF Ratio for Preeclampsia Receives FDA 510(K) Clearance

Roche Holding (VTX:ROG) Is Paying Out A Larger Dividend Than Last Year

Legacy Pharma Inc. SEZC acquired InterMune, Inc. from Roche Holding AG (SWX:ROG).

Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear

Roche Announces FDA Approves Roche’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness

Roche Holding will see a 4.2576% revenue growth shaking the market

Advancing 7 New Therapies And Poseida Acquisition Will Expand Presence In Oncology By 2025

Full year 2024 earnings: EPS misses analyst expectations

Roche Receives FDA Approval for the First Companion Diagnostic to Identify Patients with HER2-ultralow Metastatic Breast Cancer Eligible for ENHERTU

Roche Holding AG Reports Earnings Guidance for the Year 2025

Roche Announces Executive and Committee Changes

Roche's Itovebi Demonstrates Statically Significant and clinically meaningful Overall Survival Benefit in A Certain Type of HR-Positive Advanced Breast Cancer

Roche Receives FDA Clearance with CLIA Waiver for Cobas® liat Molecular Tests to Diagnose Sexually Transmitted Infections At the Point of Care

Roche Receives FDA Clearance For VENTANA DP 600 Slide Scanner In Digital Pathology

Roche Holding AG to Report Fiscal Year 2024 Results on Jan 30, 2025

Roche's Vabysmo® Prefilled Syringe Approved by European Medicines Agency for Treating Retinal Conditions

New and Updated Data for Columvi and Lunsumio At Ash 2024 Reinforce Their Potential to Improve Outcomes for People with Lymphoma

Five-Year Results Confirm Roche’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche Holding AG (VTX:ROG) Could Be Riskier Than It Looks

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials